Status:
COMPLETED
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
Lead Sponsor:
AbbVie
Conditions:
Episodic Migraine
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will assess the safety and efficacy...
Eligibility Criteria
Inclusion
- At least 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders (ICHD)-3, 2018.
- History of 4 to 14 migraine days per month on average in the 3 months prior to Screening (Visit 1) in the investigator's judgment.
Exclusion
- \- Clinically significant hematologic, endocrine, cardiovascular, cerebrovascular, pulmonary, renal, hepatic, gastrointestinal, or neurologic disease.
Key Trial Info
Start Date :
March 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 4 2023
Estimated Enrollment :
263 Patients enrolled
Trial Details
Trial ID
NCT05264129
Start Date
March 7 2022
End Date
April 4 2023
Last Update
October 8 2024
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
Achieve Clinical Research, LLC /ID# 244912
Birmingham, Alabama, United States, 35216
2
Xenoscience, Inc /ID# 243506
Phoenix, Arizona, United States, 85004
3
Excell Research, Inc /ID# 242590
Oceanside, California, United States, 92056
4
Neurological Research Institute /ID# 244161
Santa Monica, California, United States, 90404